<DOC>
	<DOCNO>NCT00584740</DOCNO>
	<brief_summary>This study ass safety efficacy AIN457 patient moderate severe active Crohn 's disease .</brief_summary>
	<brief_title>Efficacy , Safety Tolerability AIN457 Moderate Severe Active Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Male female ; 1875 year old Diagnosis Crohn 's disease least 3 month prior screen Confirmation Crohn 's disease endoscopic image examination Moderately active Crohn 's disease baseline , define : CDAI ≥220 ≤450 Active disease despite prior treatment corticosteroid least 2 week , immunosuppressant least 3 month . Treatment azathioprine , 6MP MTX allow must stable dose least 10 week , corticosteroid allow must stable dos prednisolone exceed 40 mg two week prior baseline . Immunosuppressants list , cyclosporine , tacrolimus mycophenolate , allow must stop ( washout period define protocol ) ; Body Mass Index &gt; 34 Positive PPD tuberculin skin test QuantiFeron test Any subject evidence active pulmonary disease evidence latent tuberculosis fungal infection screen within past 3 month Symptoms associate active bowel structure disease prestenotic dilation radiograph Fistulizing disease complicate sepsis and/or untreated abscess Multiple bowel surgery clinically important short bowel syndrome define inability maintain caloric intake Use certain medication specify protocol Clinical improvement due Crohn 's therapy Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Crohn 's disease , moderate , severe , active , AIN457</keyword>
</DOC>